VE-821
| CAS No. | 1232410-49-9 | Cat. No. | BCP02617 |
| Name | VE-821 | ||
| Synonyms | VE821;VE 821; | ||
| Formula | C18H16N4O3S | M. Wt | 368.41 |
| Description | VE-821 shows excellent selectivity for ATR with minimal cross-reactivity against the related PIKKs ATM, DNA-PK, mTOR and PI3K (Kis of 16 μM, 2.2 μM, >1 μM and 3.9 μM, respectively. VE-821 alone commits a large fraction of cancer cell populations to death, but it only reversibly limits cell cycle progression in normal cells, with minimal death or long-term detrimental effects. VE-821 along with cisplatin treatment shows the most marked synergy.VE-821 inhibits H2AX cell growth with IC50 of 800 nM. | ||
| Pathways | Cell Cycle/DNA Damage PI3K/Akt/mTOR | ||
| Targets | ATM/ATR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.